Study to Assess the Efficacy and Safety of NTRA-2112 on Intestinal Malabsorption in Preterm Infants

Stopped early · Phase 3 · Has a placebo group

Conditions studied: Premature Birth of Newborn, Intestinal Malabsorption

In brief

The study will evaluate the effect of NTRA-2112 on intestinal malabsorption in preterm infants.

Key facts

Study ID
NCT02510560
Run by
Elgan Pharma Ltd.
People needed
300
Starts
2016-10-09
Expected to finish
2018-04-25
Last updated by the study team
2025-08-19

Who can join

Age: 0 and older, up to 0. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.